中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

20 records (took 0.031 seconds)

    Methods of monitoring a human anti-human antibody response and inhibitors thereof
    1.
    发明授权
    Methods of monitoring a human anti-human antibody response and inhibitors thereof 失效
    监测人抗人抗体应答的方法及其抑制剂

    公开(公告)号：US08597615B2

    公开(公告)日：2013-12-03

    申请号：US13466888

    申请日：2012-05-08

    Applicant: Sirid-Aimee Kellermann ,  Larry L. Green ,  Wouter Korver

    Inventor： Sirid-Aimee Kellermann ,  Larry L. Green ,  Wouter Korver

    IPC: A61K49/00 ,  A01K67/027 ,  A01K67/00

    CPC classification number: G01N33/6854 ,  C07K16/464 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  G01N33/5088

    Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.

    Abstract translation: 本实施方案涉及鉴定和产生人或人源化抗体的方法，所述人或人源化抗体在应用于人类宿主时具有诱导人抗人抗体（HAHA）应答的风险降低。 其他方法用于预测发生HAHA反应的可能性。 还包括用于筛选抗HAHA化合物的方法。 还包括用于确定对受试者施用抗体的各种条件是否增强或抑制HAHA应答的方法。

    Antibodies to CLL-1
    5.
    发明授权
    Antibodies to CLL-1 有权
    CLL-1抗体

    公开(公告)号：US08536310B2

    公开(公告)日：2013-09-17

    申请号：US12738546

    申请日：2008-10-03

    Applicant: Arie Abo ,  Wouter Korver

    Inventor： Arie Abo ,  Wouter Korver

    IPC: C12P21/08

    CPC classification number: C07K16/2851 ,  A61K2039/505 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2319/21

    Abstract: Anti-CLL-1 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind CLL-1 and treat diseases, such as hematologic malignancies, which are characterized by expression of CLL-1.

    Abstract translation: 描述了抗CLL-1抗体及其抗原结合片段，以及包含此类抗体和抗原结合片段的药物组合物。 还描述了使用这些抗体和抗原结合区域结合CLL-1并治疗以CLL-1表达为特征的疾病如血液恶性肿瘤的方法。

    REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION
    6.
    发明申请
    REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION 失效
    通过V基因操作降低人类抗体抗体的风险

    公开(公告)号：US20120219976A1

    公开(公告)日：2012-08-30

    申请号：US13466888

    申请日：2012-05-08

    Applicant: SIRID-AIMÉE KELLERMANN ,  LARRY L. GREEN ,  WOUTER KORVER

    Inventor： SIRID-AIMÉE KELLERMANN ,  LARRY L. GREEN ,  WOUTER KORVER

    IPC: G01N33/566

    CPC classification number: G01N33/6854 ,  C07K16/464 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  G01N33/5088

    Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.

    Abstract translation: 本实施方案涉及鉴定和产生人或人源化抗体的方法，所述人或人源化抗体在应用于人类宿主时具有诱导人抗人抗体（HAHA）应答的风险降低。 其他方法用于预测发生HAHA反应的可能性。 还包括用于筛选抗HAHA化合物的方法。 还包括用于确定对受试者施用抗体的各种条件是否增强或抑制HAHA应答的方法。

    Reducing the risk of human anti-human antibodies through V gene manipulation
    9.
    发明授权
    Reducing the risk of human anti-human antibodies through V gene manipulation 失效
    通过V基因操作降低人抗人抗体的风险

    公开(公告)号：US08198508B2

    公开(公告)日：2012-06-12

    申请号：US12577696

    申请日：2009-10-12

    Applicant: Sirid-Aimee Kellermann ,  Larry L. Green ,  Wouter Korver

    Inventor： Sirid-Aimee Kellermann ,  Larry L. Green ,  Wouter Korver

    IPC: A01K67/00 ,  A01K67/027 ,  A61K49/00

    CPC classification number: G01N33/6854 ,  C07K16/464 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  G01N33/5088

    Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included. Some embodiments herein are directed to transgenic mouse embodiments relevant for HAHA responses.

    Abstract translation: 本实施方案涉及鉴定和产生人或人源化抗体的方法，所述人或人源化抗体在应用于人类宿主时具有诱导人抗人抗体（HAHA）应答的风险降低。 其他方法用于预测发生HAHA反应的可能性。 还包括用于筛选抗HAHA化合物的方法。 还包括用于确定对受试者施用抗体的各种条件是否增强或抑制HAHA应答的方法。 本文的一些实施方案涉及与HAHA反应相关的转基因小鼠实施方案。

Patent Agency Ranking